Drug targets identification of Mycobacterium tuberculosis by metabolic pathway analysis: insilico process

  • Posted on: 30 June 2017
  • By: admin

 

Magazine Home


July 2017 ARTICLE LIST >>

PharmaTutor (July - 2017)

 

ISSN: 2347 - 7881
(Volume 5, Issue 7)

 

Received On: 16/03/2017; Accepted On: 22/03/2017; Published On: 01/07/2017

 

AUTHORS:
Amiya Kumar Ghosh*1,Saptarshi Samajdar2, Shiladitya Palit3, Rupchand Pandit4
1Department of Pharmaceutical Technology,
Utkal University, Bhubaneswar, Odisha, India.
2Centre for Pharmaceutical Sciences and Natural Products,
Central University of Punjab, Bathinda, Punjab, India
3Department of Pharmaceutics, IITBHU, Varanasi, India
4Department of Pharmaceutical Science & Technology,
Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India
*amiyaghosh94@gmail.com

 

 

ABSTRACT:
Tuberculosis (TB) has been declared as a global health emergency by the World Health Organization(WHO). This has been mainly due to the emergence of multiple drug resistant strains and the synergy between tubercle bacilli and the human immunodeficiency virus (HIV). Mycobacterium tuberculosis (Mtb) is a pathogenic bacteria species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Tuberculosis (TB) is the leading cause of death in the world from a bacterial infectious disease.

 

 

How to cite this article: Ghosh AK, Samajdar S, Palit S, Pandit R;Drug targets identification of Mycobacterium tuberculosis by metabolic pathway analysis: insilico process; PharmaTutor; 2017; 5(7); 43-53

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML